Indivior to Announce Full Year 2017 Results on February 15th
Slough, UK, and Richmond, VA, 19 January 2018 – Indivior PLC (LON: INDV) today announced that it will release its full year 2017 results on February 15th at 7:00 a.m. London time (2:00 a.m. U.S. EST). The results will be available via the London Stock Exchange’s Regulatory News Service (RNS) and on the “Investors” section of the company’s website at www.indivior.com.
Key members of Indivior’s leadership team will present the full year 2017 results to analysts and investors at 12 noon London time (7:00 a.m. U.S. EST) on the same day (February 15th). The presentation will take place at The Ayres Room, Deutsche Bank, Winchester House, 75 London Wall, London EC2N 2DB. The presentation will be led by Shaun Thaxter, Chief Executive Officer, and will be followed by a question and answer session, during which other presenting members of Indivior’s leadership team, including Chief Financial Officer, Mark Crossley, Chief Scientific Officer, Christian Heidbreder, Ph.D., and Chief Legal Officer, Javier Rodriguez, will be available to address questions from qualified analysts and investors.
Access to the Live Webcast of Indivior’s Full Year 2017 Results Presentation
A live webcast of the full year 2017 results presentation also will be available to remote participants. The webcast event and materials will be available on the “Investors” section of the company’s website at www.indivior.com before the event begins on February 15th at 12 noon London time (7:00 a.m. U.S. EST). The webcast link is https://edge.media-server.com/m6/p/es78akq6. Participants also may access the full year 2017 results telephonically: US participants 1-646-828-8156; international participants 44(0)330-336-9105. Please reference confirmation number 8967922. A replay of the presentation will be available at www.indivior.com
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including AUD and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-423-8916 or jason.thompson@indivior.com